Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

Pages

79632 items
12:35 PM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

Sarepta gets gene therapy candidate, Lysogene extends runway

Lysogene S.A. (Euronext:LYS) granted Sarepta Therapeutics Inc. (NASDAQ:SRPT) exclusive, ex-European rights to LYS-SAF302, an adeno-associated virus (AAV)-mediated gene therapy. Sarepta will pay $15 million up front and make a $2.5 million equity investment in Lysogene,...
12:14 PM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

HiFiBiO Therapeutics acquires H-Immune

HiFiBiO Therapeutics (Cambridge, Mass.) acquired H-Immune Therapeutics S.A.S. (Paris, France) for an undisclosed sum. H-Immune is developing a pipeline of immuno-oncology focused human antibodies generated using the company's in vitro immunization platform. The biotech spun...
11:37 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

AbbVie, Morphic partner on antifibrotic integrins

AbbVie Inc. (NYSE:ABBV) agreed to pay Morphic Therapeutic (Waltham, Mass.) $100 million up front for exclusive options to license antifibrotic integrins to block transforming growth factor β (TGFβ) activation via multiple undisclosed targets. Morphic is responsible...
11:33 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
11:27 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

Roche culls pipeline, cuts include in-licensed, acquired programs

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...
11:26 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

WideTrial seeks to increase expanded access programs by helping companies recover costs

FDA has authorized WideTrial Inc. (San Francisco, Calif.) to charge payment for an expanded access program for critical limb ischemia (CLI) candidate PLX-PAD from Pluristem Therapeutics Inc. (NASDAQ:PSTI; Tel Aviv:PSTI) under a cost recovery program....
11:11 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Other News

Changsheng fined $1.3B after vaccine scandal

China's National Medical Products Administration (NMPA) fined Changsheng Bio-Technology Co. Ltd. (SZSE:002680) RMB7.2 billion ($1 billion) for eight counts of manufacturing violations, falsification of records and destruction of evidence associated with the illegal production of...
11:08 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...
11:06 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

Xyphos, Parker Institute steer next-gen Car T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertibleCAR platform. Xyphos President and CEO Jim Knighton told BioCentury the research will...
11:02 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Oct. 17. The PBM gave the nod to Aimovig erenumab-aooe from...

Pages